ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Nestlé Invests In Microbiome Firm

by Michael McCoy
January 12, 2015 | APPEARED IN VOLUME 93, ISSUE 2

The health science subsidiary of the food giant Nestlé has invested $65 million in Seres Health, a Cambridge, Mass.-based firm that is developing biological drugs designed to treat disease by restoring a malfunctioning microbiome. Seres recently raised $48 million from other investors. Seres says it will use the funds to move its lead product, SER-109, into Phase III clinical trials for preventing the recurrence of Clostridium difficile infection.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment